BlackRock Health Sciences Term Trust (BMEZ) Announces Final Results of Tender Offer
MWN-AI** Summary
BlackRock Health Sciences Term Trust (BMEZ) recently announced the final results of its tender offer for its outstanding common shares. The tender offer, which allowed for the repurchase of up to 40% of the Trust’s shares, officially expired on April 17, 2025. Despite the tender offer's goals, it was ultimately undersubscribed, leading to the decision to purchase all shares that were properly tendered by shareholders. This means that shareholders who participated in the tender offer will have their shares bought back by the Trust.
According to the final results, a total of 38,753,713 shares were tendered for purchase, with the purchase price set at $14.2086 per share, equating to 99.5% of the Trust’s net asset value as of the end of regular trading on the New York Stock Exchange on April 21, 2025. Payments for the shares accepted in the tender are scheduled to be made within approximately five business days after the expiration date.
This announcement serves as an important update to BMEZ shareholders and interested stakeholders. It is essential to note that this press release aims to provide information and does not represent a recommendation or solicitation regarding the shares of the Fund. Shareholders seeking detailed documentation related to the tender offer are directed to the U.S. Securities and Exchange Commission's website or to contact BlackRock directly.
BlackRock emphasizes its commitment to aiding financial well-being for investors and encourages stakeholders to access ongoing updates and performance data on the Trust via its website. It also retains the right to update statements regarding future performance, reflecting the uncertainties tied to market dynamics and various external factors.
MWN-AI** Analysis
The recent announcement by BlackRock Health Sciences Term Trust (BMEZ) regarding the final results of their tender offer holds significant insights for current and potential investors. The tender offer, which sought to repurchase up to 40% of its outstanding shares, was notably undersubscribed, with only 38,753,713 shares tendered against an offer of 40,502,046. Consequently, the Fund will proceed to purchase all properly tendered shares at a purchase price equivalent to 99.5% of its net asset value as of April 21, 2025.
From a market perspective, the undersubscription could signal a lack of confidence among investors. This could stem from concerns regarding the Fund's long-term performance or overall health sector volatility. Investors may want to analyze the reasons behind this sentiment, including market conditions, forecasted healthcare trends, or any internal Fund management issues.
The purchase price indicates a commitment to maintaining shareholder value, yet the limited interest might suggest that many investors believe the current valuation does not reflect the Fund's intrinsic worth. Given that the tender offer is concluded, investors should now focus on evaluating the implications of this trend on the Fund's NAV and overall performance.
For current shareholders, monitoring the Fund's post-tender offer NAV is crucial. A rebound in NAV could suggest that the markets have reconciled the temporary concerns resulting from the tender. Prospective investors might seek entry points around the next reporting period as the effects of recent transactions crystallize. Understanding BlackRock's broader strategy and performance metrics will be key as they provide insights into potential recovery and growth areas in the healthcare sector. Overall, prudent due diligence and market trend examination will be essential in assessing the future investment outlook for BMEZ.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
BlackRock Health Sciences Term Trust (the “Fund”) announced today the final results of the Fund’s tender offer (the “Tender Offer”) for up to 40% of its outstanding common shares (the “Shares”), which expired on April 17, 2025.
The Tender Offer was undersubscribed. Therefore, in accordance with the terms and conditions of the Tender Offer, the Fund will purchase all Shares properly tendered from all tendering shareholders. Payment for Shares tendered and accepted are expected to be made within approximately five business days after the expiration date (anticipated to be April 25, 2025).
The final results of the Tender Offer are provided in the table below:
Fund Name | Ticker | CUSIP | Number of Shares Offered for Repurchase | Number of Tendered Shares to be Purchased | Purchase Price* |
BlackRock Health Sciences Term Trust | BMEZ | 09260E105 | 40,502,046 | 38,753,713 | 14.2086 |
*Equal to 99.5% of the Fund’s net asset value per Share as of the close of regular trading on the New York Stock Exchange on April 21, 2025 (the business day immediately following the expiration date of the Tender Offer).
Important Notice
This press release is for informational purposes only and shall not constitute a recommendation, an offer to purchase or a solicitation of an offer to sell any common shares of the Fund. The offer to purchase the Fund’s common shares was made only pursuant to an offer to purchase, a related letter of transmittal and other documents filed with the U.S. Securities and Exchange Commission (“SEC”) as exhibits to a tender offer statement on Schedule TO. Shareholders may obtain a free copy of the offer to purchase and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Fund.
About BlackRock
BlackRock’s purpose is to help more and more people experience financial well-being. As a fiduciary to investors and a leading provider of financial technology, we help millions of people build savings that serve them throughout their lives by making investing easier and more affordable. For additional information on BlackRock, please visit www.blackrock.com/corporate .
Availability of Fund Updates
BlackRock will update performance and certain other data for the Fund on a monthly basis on its website in the “Closed-end Funds” section of www.blackrock.com as well as certain other material information as necessary from time to time. Investors and others are advised to check the website for updated performance information and the release of other material information about the Fund. This reference to BlackRock’s website is intended to allow investors public access to information regarding the Fund and does not, and is not intended to, incorporate BlackRock’s website in this release.
Forward-Looking Statements
This press release, and other statements that BlackRock or the Fund may make, may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act, with respect to the Fund’s or BlackRock’s future financial or business performance, strategies or expectations. Forward-looking statements are typically identified by words or phrases such as “trend,” “potential,” “opportunity,” “pipeline,” “believe,” “comfortable,” “expect,” “anticipate,” “current,” “intention,” “estimate,” “position,” “assume,” “outlook,” “continue,” “remain,” “maintain,” “sustain,” “seek,” “achieve,” and similar expressions, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may” or similar expressions.
BlackRock cautions that forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and BlackRock assumes no duty to and does not undertake to update forward-looking statements. Actual results could differ materially from those anticipated in forward-looking statements and future results could differ materially from historical performance.
With respect to the Fund, the following factors, among others, could cause actual events to differ materially from forward-looking statements or historical performance: (1) changes and volatility in political, economic or industry conditions, the interest rate environment, foreign exchange rates or financial and capital markets, which could result in changes in demand for the Fund or in the Fund’s net asset value; (2) the relative and absolute investment performance of the Fund and its investments; (3) the impact of increased competition; (4) the unfavorable resolution of any legal proceedings; (5) the extent and timing of any distributions or share repurchases; (6) the impact, extent and timing of technological changes; (7) the impact of legislative and regulatory actions and reforms, and regulatory, supervisory or enforcement actions of government agencies relating to the Fund or BlackRock, as applicable; (8) terrorist activities, international hostilities, health epidemics and/or pandemics and natural disasters, which may adversely affect the general economy, domestic and local financial and capital markets, specific industries or BlackRock; (9) BlackRock’s ability to attract and retain highly talented professionals; (10) the impact of BlackRock electing to provide support to its products from time to time; and (11) the impact of problems at other financial institutions or the failure or negative performance of products at other financial institutions.
Annual and Semi-Annual Reports and other regulatory filings of the Fund with the SEC are accessible on the SEC's website at www.sec.gov and on BlackRock’s website at www.blackrock.com , and may discuss these or other factors that affect the Fund. The information contained on BlackRock’s website is not a part of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250421994187/en/
1-800-882-0052
FAQ**
How does the undersubscription of the Tender Offer for BlackRock Health Sciences Trust II of Beneficial Interest BMEZ impact the Fund's net asset value and future investment strategies?
What are the potential risks and uncertainties mentioned regarding the performance of BlackRock Health Sciences Trust II of Beneficial Interest BMEZ that investors should consider before participating in the next Tender Offer?
How might changes in the interest rate environment affect the demand for shares of BlackRock Health Sciences Trust II of Beneficial Interest BMEZ following the recent Tender Offer results?
Can you elaborate on how BlackRock’s commitment to financial technology might influence the investment performance of BlackRock Health Sciences Trust II of Beneficial Interest BMEZ moving forward?
**MWN-AI FAQ is based on asking OpenAI questions about BlackRock Health Sciences Term Trust of Beneficial Interest (NYSE: BMEZ).
NASDAQ: BMEZ
BMEZ Trading
1.74% G/L:
$14.64 Last:
219,134 Volume:
$14.58 Open:
